AstraZeneca unveiled its new Discovery Centre (DISC) in Cambridge, UK, a new, £1 billion state-of-the-art R&D facility designed to the highest environmental standards and accommodating more than 2,200 research scientists.
 
The new facility will include advanced robotics, high-throughput screening and AI-driven technology. It will support AZ’s focus on specialized and precision medicines and foster the discovery and development of next generation therapeutics, including nucleotide-based, gene-editing and cell therapies.
 
Pascal Soriot, Chief Executive Officer, AstraZeneca, said: “Our ambition today is to not only unveil a building, but to also drive the next wave of scientific innovation. Our new Discovery Centre in Cambridge raises the bar for sustainable R&D and global collaboration across our industry. It will allow us to break new boundaries in the understanding of disease biology, bring life-changing medicines to patients and power the next stage of our company’s growth.”
 
The Company invests more than $7 billion in R&D globally each year, most of which takes place in the UK. The Centre will help further nurture partnerships, develop the next generation of science leaders and accelerate productivity.
 
The Cambridge Biomedical Campus and the 19,000m² lab space, is in close proximity to leading hospitals, the University of Cambridge, other research institutions. The Company has over 200 active collaborations in the region and more than 2,000 around the world across academia, biotech and industry.